Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced ...

Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesionsMP0712 Radio-DARPin leverages rapid ...

MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in ...

Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was ...

Strategic Focus on Data and AI A key highlight from the presentation was ExlService’s accelerating transition toward data and AI-led services, which now constitute 54.2% of total revenue at $278.8 ...

Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use - SAN DIEGO and TOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.

Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking ...

SYRACUSE, NY / ACCESS Newswire / November 11, 2025 / Repair Biotechnologies, Inc. ( today announced the recent presentation of preclinical data at American Heart Association's (AHA) Scientific ...

East Palo City Council on Tuesday postponed a five-year contract renewal of its Flock Automated License Plate Reader ...

Struggling with your slides? Here's how Gemini's latest updates can help you polish your presentation, and who can access them.

This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to ...

Looking ahead to 2026, Vertiv expects AI-driven data center demand to remain strong. The company anticipates continued significant organic sales growth, supported by accelerated investments in supply ...